董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Hayden | 男 | Director | 68 | 12.28万美元 | 未持股 | 2020-03-01 |
| Anat Naschitz | 女 | Director | 52 | 未披露 | 未持股 | 2020-03-01 |
| Gregory Grunberg | 男 | Director | 47 | 未披露 | 未持股 | 2020-03-01 |
| Derek DiRocco | 男 | Director | 39 | 未披露 | 未持股 | 2020-03-01 |
| Derek DiRocco | -- | Director | 39 | 未披露 | 未持股 | 2020-03-01 |
| Derek Paul Di Rocco | 男 | Director | 39 | 未披露 | 未持股 | 2020-03-01 |
| Rohan Palekar | 男 | Chief Executive Officer and Director | 54 | 102.26万美元 | 未持股 | 2020-03-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ram Waisbourd | 男 | Chief Operating Officer and Chief Business Officer | 53 | 31.80万美元 | 未持股 | 2020-03-01 |
| Ryan Martins | 男 | Chief Financial Officer | 43 | 未披露 | 未持股 | 2020-03-01 |
| Hank Mansbach | 男 | Chief Medical Officer | 55 | 76.49万美元 | 未持股 | 2020-03-01 |
| Quoc Le Nguyen | 男 | Chief Technical Operations Officer and Head of Quality | 52 | 55.78万美元 | 未持股 | 2020-03-01 |
| Rohan Palekar | 男 | Chief Executive Officer and Director | 54 | 102.26万美元 | 未持股 | 2020-03-01 |
董事简历
中英对照 | 中文 | 英文- Michael Hayden
-
Michael Hayden于2012年5月加入梯瓦制药（Teva），担任全球研发部总裁和首席科学官。他目前还担任British Columbia大学遗传医学基拉姆教授，并是人类遗传学和分子医学的加拿大研究主席。他还担任British Columbia大学分子医学与治疗学中心的创始人和资深科学家。加入梯瓦制药前，他创立了三家生物技术公司NeuroVir、Aspreva Pharmaceuticals和Xenon Pharmaceuticals Inc.，从2000年到2012年，担任Xenon的首席科学官。从2010年到2011年，他还担任Med Biogene Inc.的董事。他获得过多个奖项，包括于2011年获得加拿大盖尔德纳怀特曼奖；于2010年获得加拿大最高荣誉勋章，该奖为加拿大政府授予其公民以表彰杰出成就的最高荣誉；于1998年获得加拿大临床调查协会（Canadian Society of Clinical Investigation）的杰出科学家奖，于2008年被授予“加拿大年度健康研究员”称号。Hayden博士于1975年在Cape Town大学获得医学外科医学士；于1979年获得遗传学博士学位；于1979年获得儿童健康文凭。他于1982年在哈佛大学医学院（Harvard Medical School）获得内科学和临床遗传学的美国专科认证；于1984年在British Columbia大学获得内科学医生学会会员。
Michael Hayden,has served as a member of Board of Directors since September 2019. Dr. Hayden is the Lead director of the Board of Directors and serves as the Chair of Compensation Committee, is a member of Nominating and Corporate Governance Committee, and a member of Audit Committee. Dr. Hayden has been the Chief Executive Officer of Prilenia Therapeutics B.V., a clinical stage biotechnology company since September 2018. From September 2012 to December 2017, Dr. Hayden served as Chief Science Officer and President of Global Research and Development at Teva Pharmaceutical Industries Ltd., a public pharmaceutical company. Dr. Hayden has founded a number of biotechnology companies, including Aspreva Pharmaceuticals Limited, a private pharmaceutical company; Neurovir Therapeutics, Inc., a private biopharmaceutical company; Xenon Pharmaceuticals Inc., a public clinical-stage biopharmaceutical company; and 89bio, Inc., a public clinical-stage biopharma company. Dr. Hayden has served as a member of the Board of Directors for each of Ionis Pharmaceuticals Inc., a public biotechnology company, since September 2018; 89bio since April 2018, and Xenon Pharmaceuticals Inc. from November 1996 to June 2022. From September 2018 to June 2020, Dr. Hayden also served as the executive chairman of the Board of Directors of Prilenia. Dr. Hayden is also a Killam Professor of Medical Genetics at the University of British Columbia, a Founder and Senior Scientist at the Centre for Molecular Medicine and Therapeutics, and a Canada Research Chair in Human Genetics and Molecular Medicine. Dr. Hayden holds an M.B., Ch.B. (M.D.) and a Ph.D. degree in Genetics from the University of Cape Town. He is board certified by the American Societies of Internal Medicine and Medical Genetics. He is also certified by the Royal College of Physicians of Canada (Internal Medicine). - Michael Hayden于2012年5月加入梯瓦制药（Teva），担任全球研发部总裁和首席科学官。他目前还担任British Columbia大学遗传医学基拉姆教授，并是人类遗传学和分子医学的加拿大研究主席。他还担任British Columbia大学分子医学与治疗学中心的创始人和资深科学家。加入梯瓦制药前，他创立了三家生物技术公司NeuroVir、Aspreva Pharmaceuticals和Xenon Pharmaceuticals Inc.，从2000年到2012年，担任Xenon的首席科学官。从2010年到2011年，他还担任Med Biogene Inc.的董事。他获得过多个奖项，包括于2011年获得加拿大盖尔德纳怀特曼奖；于2010年获得加拿大最高荣誉勋章，该奖为加拿大政府授予其公民以表彰杰出成就的最高荣誉；于1998年获得加拿大临床调查协会（Canadian Society of Clinical Investigation）的杰出科学家奖，于2008年被授予“加拿大年度健康研究员”称号。Hayden博士于1975年在Cape Town大学获得医学外科医学士；于1979年获得遗传学博士学位；于1979年获得儿童健康文凭。他于1982年在哈佛大学医学院（Harvard Medical School）获得内科学和临床遗传学的美国专科认证；于1984年在British Columbia大学获得内科学医生学会会员。
- Michael Hayden,has served as a member of Board of Directors since September 2019. Dr. Hayden is the Lead director of the Board of Directors and serves as the Chair of Compensation Committee, is a member of Nominating and Corporate Governance Committee, and a member of Audit Committee. Dr. Hayden has been the Chief Executive Officer of Prilenia Therapeutics B.V., a clinical stage biotechnology company since September 2018. From September 2012 to December 2017, Dr. Hayden served as Chief Science Officer and President of Global Research and Development at Teva Pharmaceutical Industries Ltd., a public pharmaceutical company. Dr. Hayden has founded a number of biotechnology companies, including Aspreva Pharmaceuticals Limited, a private pharmaceutical company; Neurovir Therapeutics, Inc., a private biopharmaceutical company; Xenon Pharmaceuticals Inc., a public clinical-stage biopharmaceutical company; and 89bio, Inc., a public clinical-stage biopharma company. Dr. Hayden has served as a member of the Board of Directors for each of Ionis Pharmaceuticals Inc., a public biotechnology company, since September 2018; 89bio since April 2018, and Xenon Pharmaceuticals Inc. from November 1996 to June 2022. From September 2018 to June 2020, Dr. Hayden also served as the executive chairman of the Board of Directors of Prilenia. Dr. Hayden is also a Killam Professor of Medical Genetics at the University of British Columbia, a Founder and Senior Scientist at the Centre for Molecular Medicine and Therapeutics, and a Canada Research Chair in Human Genetics and Molecular Medicine. Dr. Hayden holds an M.B., Ch.B. (M.D.) and a Ph.D. degree in Genetics from the University of Cape Town. He is board certified by the American Societies of Internal Medicine and Medical Genetics. He is also certified by the Royal College of Physicians of Canada (Internal Medicine).
- Anat Naschitz
-
Anat Naschitz，2013年3月起，担任本公司董事；2014年12月23日，再次当选为董事，任职直到下一届股东大会。她现为私营公司 Treato Ltd., Tyto Care Ltd. 、Axiom One Ltd.的董事，以及OrbiMed Advisors LLC的管理合伙人。她曾是Apax Partners的负责人，专门从事医疗器械公司的投资；也曾是McKinsey and Company的助理负责人，管理着国际团队的管理，这些团队为大型制药企业的高级管理层，提供策略、并购、成立新公司、研发、营销等方面的服务。她在INSEAD获得工商管理硕士学位，在以色列的Tel-Aviv University获得法律学士学位。
Anat Naschitz has served as a member of our board of directors since January 2018 and played a key role in creating 89Bio Ltd. as a spinout from a pharmaceutical company. Ms. Naschitz has served as Managing Director at OrbiMed, a global healthcare investment firm, since January 2010. Ms. Naschitz has over 20 years of healthcare experience. Previously, Ms. Naschitz created, invested in and advised healthcare companies across stages and substance. She was an Associate Partner with McKinsey in London from 1995 to 2002 where she managed strategy, company formation through spinouts and mergers and acquisitions projects for senior management of the world’s leading pharmaceutical and biotechnology companies. Subsequently Ms. Naschitz was a Principal at Apax Partners, where she invested in healthcare companies. She currently serves on the boards of biotech and digital health companies and served on the board of Medigus Ltd., a medical device company, from March 2013 to June 2017. Ms. Naschitz earned her M.B.A. at INSEAD and her L.L.B. at Tel Aviv University. - Anat Naschitz，2013年3月起，担任本公司董事；2014年12月23日，再次当选为董事，任职直到下一届股东大会。她现为私营公司 Treato Ltd., Tyto Care Ltd. 、Axiom One Ltd.的董事，以及OrbiMed Advisors LLC的管理合伙人。她曾是Apax Partners的负责人，专门从事医疗器械公司的投资；也曾是McKinsey and Company的助理负责人，管理着国际团队的管理，这些团队为大型制药企业的高级管理层，提供策略、并购、成立新公司、研发、营销等方面的服务。她在INSEAD获得工商管理硕士学位，在以色列的Tel-Aviv University获得法律学士学位。
- Anat Naschitz has served as a member of our board of directors since January 2018 and played a key role in creating 89Bio Ltd. as a spinout from a pharmaceutical company. Ms. Naschitz has served as Managing Director at OrbiMed, a global healthcare investment firm, since January 2010. Ms. Naschitz has over 20 years of healthcare experience. Previously, Ms. Naschitz created, invested in and advised healthcare companies across stages and substance. She was an Associate Partner with McKinsey in London from 1995 to 2002 where she managed strategy, company formation through spinouts and mergers and acquisitions projects for senior management of the world’s leading pharmaceutical and biotechnology companies. Subsequently Ms. Naschitz was a Principal at Apax Partners, where she invested in healthcare companies. She currently serves on the boards of biotech and digital health companies and served on the board of Medigus Ltd., a medical device company, from March 2013 to June 2017. Ms. Naschitz earned her M.B.A. at INSEAD and her L.L.B. at Tel Aviv University.
- Gregory Grunberg
-
Gregory Grunberg自2018年4月以来一直担任我们的董事会成员。Grunberg博士从2012年2月开始一直担任Longitude Capital Management Co.，LLC的常务董事，这是一家风险投资公司。加入Longitude之前，他曾担任Rho Ventures公司（风险投资公司）的负责人（从2007年5月到2012年1月）。Grunberg博士在内科和加州大学旧金山分校（University of California，San Francisco）和Kaiser Permanente保持有限的临床实践。Grunberg博士自2016年4月起担任制药公司Kala Pharmaceuticals Inc.的董事，自2018年4月起担任私人梦百合服务公司WelbeHealth LLC的董事。自2017年9月以来，他一直担任私人生物技术公司Sydnexis，Inc.的董事会观察员。他曾于2014年8月至2018年8月担任GI Partners收购的California Cryobank的董事会成员，并领导Longitude&8217；s Practice Fusion（被Allscripts HealthcareSolutions，Inc.收购）的投资。在Rho Ventures任职期间，他于2010年6月至2011年12月担任Aquesys Inc.（被Allergan plc收购）的董事会成员，2011年6月至2012年2月担任Sarcode Bioscience Inc.（被Shire plc收购）和PHT Corporation（被eResearch Technology收购）的董事会观察员，Inc.）从2010年11月到2012年11月。Grunberg博士在杜克大学（Duke University）获得硕士学位和工商管理硕士学位，在阿默斯特学院（Amherst College）获得经济学和英语学士学位。
Gregory Grunberg has served as a member of our board of directors since April 2018. Dr. Grunberg has been a Managing Director at Longitude Capital Management Co., LLC, a venture capital firm, since February 2012. Prior to joining Longitude, Dr. Grunberg was a Principal at Rho Ventures, a venture capital firm, where he worked from May 2007 to January 2012. Dr. Grunberg maintains a limited clinical practice in internal medicine and affiliations with University of California, San Francisco and Kaiser Permanente. Dr. Grunberg has served on the boards of Kala Pharmaceuticals Inc., a pharmaceutical company, since April 2016 and WelbeHealth LLC, a private healthcare services company, since April 2018. He has served as a board observer at Sydnexis, Inc., a private biotechnology company, since September 2017. He previously served on the board of California Cryobank acquired by GI Partners from August 2014 to August 2018 and led Longitude’s investment in Practice Fusion (acquired by Allscripts Healthcare Solutions, Inc.). While at Rho Ventures he served on the board of AqueSys Inc. (acquired by Allergan plc) from June 2010 to December 2011 and was a board observer at both SARCode Bioscience Inc. (acquired by Shire plc) from June 2011 to February 2012 and PHT Corporation (acquired by eResearchTechnology, Inc.) from November 2010 to November 2012. Dr. Grunberg earned his M.D. and M.B.A. from Duke University and his A.B. in Economics and English from Amherst College. - Gregory Grunberg自2018年4月以来一直担任我们的董事会成员。Grunberg博士从2012年2月开始一直担任Longitude Capital Management Co.，LLC的常务董事，这是一家风险投资公司。加入Longitude之前，他曾担任Rho Ventures公司（风险投资公司）的负责人（从2007年5月到2012年1月）。Grunberg博士在内科和加州大学旧金山分校（University of California，San Francisco）和Kaiser Permanente保持有限的临床实践。Grunberg博士自2016年4月起担任制药公司Kala Pharmaceuticals Inc.的董事，自2018年4月起担任私人梦百合服务公司WelbeHealth LLC的董事。自2017年9月以来，他一直担任私人生物技术公司Sydnexis，Inc.的董事会观察员。他曾于2014年8月至2018年8月担任GI Partners收购的California Cryobank的董事会成员，并领导Longitude&8217；s Practice Fusion（被Allscripts HealthcareSolutions，Inc.收购）的投资。在Rho Ventures任职期间，他于2010年6月至2011年12月担任Aquesys Inc.（被Allergan plc收购）的董事会成员，2011年6月至2012年2月担任Sarcode Bioscience Inc.（被Shire plc收购）和PHT Corporation（被eResearch Technology收购）的董事会观察员，Inc.）从2010年11月到2012年11月。Grunberg博士在杜克大学（Duke University）获得硕士学位和工商管理硕士学位，在阿默斯特学院（Amherst College）获得经济学和英语学士学位。
- Gregory Grunberg has served as a member of our board of directors since April 2018. Dr. Grunberg has been a Managing Director at Longitude Capital Management Co., LLC, a venture capital firm, since February 2012. Prior to joining Longitude, Dr. Grunberg was a Principal at Rho Ventures, a venture capital firm, where he worked from May 2007 to January 2012. Dr. Grunberg maintains a limited clinical practice in internal medicine and affiliations with University of California, San Francisco and Kaiser Permanente. Dr. Grunberg has served on the boards of Kala Pharmaceuticals Inc., a pharmaceutical company, since April 2016 and WelbeHealth LLC, a private healthcare services company, since April 2018. He has served as a board observer at Sydnexis, Inc., a private biotechnology company, since September 2017. He previously served on the board of California Cryobank acquired by GI Partners from August 2014 to August 2018 and led Longitude’s investment in Practice Fusion (acquired by Allscripts Healthcare Solutions, Inc.). While at Rho Ventures he served on the board of AqueSys Inc. (acquired by Allergan plc) from June 2010 to December 2011 and was a board observer at both SARCode Bioscience Inc. (acquired by Shire plc) from June 2011 to February 2012 and PHT Corporation (acquired by eResearchTechnology, Inc.) from November 2010 to November 2012. Dr. Grunberg earned his M.D. and M.B.A. from Duke University and his A.B. in Economics and English from Amherst College.
- Derek DiRocco
-
暂无中文简介
Derek DiRocco has served as a member of our board of directors since April 2018. Dr. DiRocco has been a principal at RA Capital Management, LLC, an investment advisory firm that invests in healthcare and life science companies, since December 2017 and was previously an analyst from June 2015 to December 2017 and an associate from July 2013 to June 2015. Dr. DiRocco earned his Ph.D. in Pharmacology from the University of Washington and his B.A. in Biology from College of the Holy Cross. -
暂无中文简介
- Derek DiRocco has served as a member of our board of directors since April 2018. Dr. DiRocco has been a principal at RA Capital Management, LLC, an investment advisory firm that invests in healthcare and life science companies, since December 2017 and was previously an analyst from June 2015 to December 2017 and an associate from July 2013 to June 2015. Dr. DiRocco earned his Ph.D. in Pharmacology from the University of Washington and his B.A. in Biology from College of the Holy Cross.
- Derek DiRocco
-
暂无中文简介
Derek DiRocco has served as a member of our board of directors since September 2019. Dr. DiRocco has been a Principal at RA Capital Management, L.P., or RA Capital, an investment advisory firm that invests in healthcare and life science companies and a major shareholder of our company, since December 2017 and was previously an analyst at RA Capital from June 2015 to December 2017. Dr. DiRocco has served on the board of directors of 89bio, Inc. since April 2018 and on the board of directors for iTeos Therapeutics, Inc. since March 2020. Dr. DiRocco holds a B.A. in Biology from College of the Holy Cross and a Ph.D. in pharmacology from the University of Washington. -
暂无中文简介
- Derek DiRocco has served as a member of our board of directors since September 2019. Dr. DiRocco has been a Principal at RA Capital Management, L.P., or RA Capital, an investment advisory firm that invests in healthcare and life science companies and a major shareholder of our company, since December 2017 and was previously an analyst at RA Capital from June 2015 to December 2017. Dr. DiRocco has served on the board of directors of 89bio, Inc. since April 2018 and on the board of directors for iTeos Therapeutics, Inc. since March 2020. Dr. DiRocco holds a B.A. in Biology from College of the Holy Cross and a Ph.D. in pharmacology from the University of Washington.
- Derek Paul Di Rocco
-
Derek Paul Di Rocco，Di Rocco 博士自2020年起担任RA Capital Management,L.P.（RA Capital，一家致力于医疗保健及生命科学领域循证投资的多阶段投资管理公司）的合伙人，彼自2017年至2020年曾担任其负责人，并在2013年加入RA Capital 。Di Rocco 博士作为RA Capital 的代表，自2019年9月起担任Achilles Therapeutics plc（纳斯达克：ACHL）的非执行董事，并自2020年12月、2020年8月、2020年3月及2018年3月起分别担任Werewolf Therapeutics,Inc.（纳斯达克：HOWL）、Connect Biopharma Holdings Limited（纳斯达克：CNTB）、iTeos Therapeutics,Inc.（纳斯达克：ITOS）及89bio,Inc.（纳斯达克：ETNB）的非执行董事。于2020年3月获委任为北海康成制药有限公司董事，并于2021年6月21日调任非执行董事。Di Rocco 博士于2002年5月在圣十字学院获得生物学学士学位，并于2009年8月在华盛顿大学获得药理学博士学位。于2021年06月21日获委任为北海康成制药有限公司提名及企业管治委员会委员。
Derek Paul Di Rocco,has served as a member of Connect Biopharma Holdings Limited board of directors since August 2020. Dr. DiRocco has been a principal at RA Capital Management since December 2017 and was previously an analyst from June 2015 to December 2017 and an associate from July 2013 to June 2015. Dr. DiRocco has served on the boards of directors of iTeos Therapeutics,Inc.,CANbridge Pharmaceuticals Inc.,Achilles Therapeutics Ltd. and 89bio,Inc. since March 2020,February 2020,September 2019 and May 2018,respectively. Dr. DiRocco holds a B.A. in Biology from College of the Holy Cross and a Ph.D. in Pharmacology from the University of Washington. - Derek Paul Di Rocco，Di Rocco 博士自2020年起担任RA Capital Management,L.P.（RA Capital，一家致力于医疗保健及生命科学领域循证投资的多阶段投资管理公司）的合伙人，彼自2017年至2020年曾担任其负责人，并在2013年加入RA Capital 。Di Rocco 博士作为RA Capital 的代表，自2019年9月起担任Achilles Therapeutics plc（纳斯达克：ACHL）的非执行董事，并自2020年12月、2020年8月、2020年3月及2018年3月起分别担任Werewolf Therapeutics,Inc.（纳斯达克：HOWL）、Connect Biopharma Holdings Limited（纳斯达克：CNTB）、iTeos Therapeutics,Inc.（纳斯达克：ITOS）及89bio,Inc.（纳斯达克：ETNB）的非执行董事。于2020年3月获委任为北海康成制药有限公司董事，并于2021年6月21日调任非执行董事。Di Rocco 博士于2002年5月在圣十字学院获得生物学学士学位，并于2009年8月在华盛顿大学获得药理学博士学位。于2021年06月21日获委任为北海康成制药有限公司提名及企业管治委员会委员。
- Derek Paul Di Rocco,has served as a member of Connect Biopharma Holdings Limited board of directors since August 2020. Dr. DiRocco has been a principal at RA Capital Management since December 2017 and was previously an analyst from June 2015 to December 2017 and an associate from July 2013 to June 2015. Dr. DiRocco has served on the boards of directors of iTeos Therapeutics,Inc.,CANbridge Pharmaceuticals Inc.,Achilles Therapeutics Ltd. and 89bio,Inc. since March 2020,February 2020,September 2019 and May 2018,respectively. Dr. DiRocco holds a B.A. in Biology from College of the Holy Cross and a Ph.D. in Pharmacology from the University of Washington.
- Rohan Palekar
-
Rohan Palekar， 2012年3月加入Avanir，担任高级副总裁兼商业总监。他拥有20多年生物制药领域的经验，曾从事过很多著名品牌包括Remicade、 Stelara和研究型疗法MDV3100。他最近的商业领导职务是担任Medivation制药公司商业总监，负责所有商业活动、化学、制造和控制、医学事务和公共关系。在Medivation之前，他在强生公司工作了16年（1991年-2008年），担任过很多高级商业和战略管理职位，最近职位是强生子公司Centocor市场营销副主管，成功启动了Remicade的两项新的适应症。这之前，他是免疫学全球副主管，消费保健品和特效药市场营销负责人。他拥有阿摩司达特茅斯学院塔克商学院的工商管理硕士学位，孟买大学会计学位和法学学位。
Rohan Palekar has served as our Chief Executive Officer and a member of our board of directors since June 2018. Prior to joining our company, Mr. Palekar served as the president and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a specialty pharmaceutical company, from December 2015 to July 2017 where he led the company following its acquisition by Otsuka Pharmaceutical Co., Ltd. in 2015. Mr. Palekar also served as Executive Vice President and Chief Operating Officer of Avanir in 2015 and as Senior Vice President and Chief Commercial Officer of Avanir from March 2012 to March 2015. Prior to Avanir, Mr. Palekar served as Chief Commercial Officer for Medivation, Inc., a biopharmaceutical company, from 2008 to 2011 where he was responsible for all commercial activities, chemistry, manufacturing and controls, medical affairs and public relations functions. Prior to Medivation, Mr. Palekar spent over 16 years at Johnson & Johnson, a diversified healthcare company, in various senior commercial and strategic management roles. Mr. Palekar earned his M.B.A. from the Tuck School of Business at Dartmouth College, his B.Com. in Accounting from the University of Mumbai and his L.L.B. in Law from the University of Mumbai. - Rohan Palekar， 2012年3月加入Avanir，担任高级副总裁兼商业总监。他拥有20多年生物制药领域的经验，曾从事过很多著名品牌包括Remicade、 Stelara和研究型疗法MDV3100。他最近的商业领导职务是担任Medivation制药公司商业总监，负责所有商业活动、化学、制造和控制、医学事务和公共关系。在Medivation之前，他在强生公司工作了16年（1991年-2008年），担任过很多高级商业和战略管理职位，最近职位是强生子公司Centocor市场营销副主管，成功启动了Remicade的两项新的适应症。这之前，他是免疫学全球副主管，消费保健品和特效药市场营销负责人。他拥有阿摩司达特茅斯学院塔克商学院的工商管理硕士学位，孟买大学会计学位和法学学位。
- Rohan Palekar has served as our Chief Executive Officer and a member of our board of directors since June 2018. Prior to joining our company, Mr. Palekar served as the president and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a specialty pharmaceutical company, from December 2015 to July 2017 where he led the company following its acquisition by Otsuka Pharmaceutical Co., Ltd. in 2015. Mr. Palekar also served as Executive Vice President and Chief Operating Officer of Avanir in 2015 and as Senior Vice President and Chief Commercial Officer of Avanir from March 2012 to March 2015. Prior to Avanir, Mr. Palekar served as Chief Commercial Officer for Medivation, Inc., a biopharmaceutical company, from 2008 to 2011 where he was responsible for all commercial activities, chemistry, manufacturing and controls, medical affairs and public relations functions. Prior to Medivation, Mr. Palekar spent over 16 years at Johnson & Johnson, a diversified healthcare company, in various senior commercial and strategic management roles. Mr. Palekar earned his M.B.A. from the Tuck School of Business at Dartmouth College, his B.Com. in Accounting from the University of Mumbai and his L.L.B. in Law from the University of Mumbai.
高管简历
中英对照 | 中文 | 英文- Ram Waisbourd
Ram Waisbourd自2018年5月起担任我们的首席运营官和首席商务官。在加入我们公司之前，Waisbourd先生于2016年11月至2018年4月担任制药公司梯瓦制药工业有限公司（Teva Pharmaceutical Industries Ltd.）全球研究与开发战略与转型Vice President，负责梯瓦研究与开发战略，新型管道融资交易和数字计划。Waisbourd先生还于2015年9月至2016年10月担任Teva全球研究与开发转型举措和运营Vice President，并于2012年8月至2015年8月担任研究与开发办公室高级主任兼主任。此前，Waisbourd先生曾担任生物技术公司Xtl BiopharmaceuticalsLtd.业务发展Vice President和投资基金Biomedical Investments Vice President。Waisbourd先生在特拉维夫大学（Tel-Aviv University）获得工商管理硕士学位和理学学士学位。宾夕法尼亚大学沃顿商学院经济学学士学位。
Ram Waisbourd has served as our Chief Operating Officer and Chief Business Officer since May 2018. Prior to joining our company, Mr. Waisbourd served as Vice President of Strategy and Transformation, Global Research and Development, at Teva Pharmaceutical Industries Ltd., a pharmaceutical company, from November 2016 to April 2018 where he was responsible for Teva research and development strategy, novel pipeline funding transactions and digital initiatives. Mr. Waisbourd also served as Vice President of Transformational Initiatives and Operations, Global Research and Development at Teva from September 2015 to October 2016 and Senior Director, Chief of the Research and Development Office from August 2012 to August 2015. Previously, Mr. Waisbourd served as Vice President of Business Development of XTL Biopharmaceuticals Ltd., a biotechnology company, and as Vice President of Biomedical Investments, an investment fund. Mr. Waisbourd earned his M.B.A from Tel-Aviv University and his B.Sc. in Economics from The Wharton School at the University of Pennsylvania.- Ram Waisbourd自2018年5月起担任我们的首席运营官和首席商务官。在加入我们公司之前，Waisbourd先生于2016年11月至2018年4月担任制药公司梯瓦制药工业有限公司（Teva Pharmaceutical Industries Ltd.）全球研究与开发战略与转型Vice President，负责梯瓦研究与开发战略，新型管道融资交易和数字计划。Waisbourd先生还于2015年9月至2016年10月担任Teva全球研究与开发转型举措和运营Vice President，并于2012年8月至2015年8月担任研究与开发办公室高级主任兼主任。此前，Waisbourd先生曾担任生物技术公司Xtl BiopharmaceuticalsLtd.业务发展Vice President和投资基金Biomedical Investments Vice President。Waisbourd先生在特拉维夫大学（Tel-Aviv University）获得工商管理硕士学位和理学学士学位。宾夕法尼亚大学沃顿商学院经济学学士学位。
- Ram Waisbourd has served as our Chief Operating Officer and Chief Business Officer since May 2018. Prior to joining our company, Mr. Waisbourd served as Vice President of Strategy and Transformation, Global Research and Development, at Teva Pharmaceutical Industries Ltd., a pharmaceutical company, from November 2016 to April 2018 where he was responsible for Teva research and development strategy, novel pipeline funding transactions and digital initiatives. Mr. Waisbourd also served as Vice President of Transformational Initiatives and Operations, Global Research and Development at Teva from September 2015 to October 2016 and Senior Director, Chief of the Research and Development Office from August 2012 to August 2015. Previously, Mr. Waisbourd served as Vice President of Business Development of XTL Biopharmaceuticals Ltd., a biotechnology company, and as Vice President of Biomedical Investments, an investment fund. Mr. Waisbourd earned his M.B.A from Tel-Aviv University and his B.Sc. in Economics from The Wharton School at the University of Pennsylvania.
- Ryan Martins
Ryan Martins自2019年7月起担任我们的首席财务官，此前自2019年4月起担任我们的顾问。在加入我们公司之前，马丁斯先生于2018年3月至2018年10月在RevolutionMedicines，Inc.担任首席财务官，负责财务职能的所有方面，包括财务会计，资本规划，审计，税务和投资者关系。在Revolution Medicines之前，马丁斯先生于2015年9月至2018年3月担任Ultragenyx Pharmaceutical，Inc.的Vice President兼公司战略和投资者关系主管，负责战略规划，资金筹集，投资者关系和协助业务发展。在Ultragenyx之前，Martins先生于2001年至2006年在Chiron Corporation担任运营角色后，在Jefferies，Lazard和Barclays/Lehman Brothers担任了近10年的生物技术分析师。Martins先生获得了理学学士学位。St.Xavier&8217；s College生命科学硕士学位，Virginia Tech生物学硕士学位和U.C.Berkeley Haas商学院工商管理硕士学位。
Ryan Martins has served as our Chief Financial Officer since July 2019 and previously served as our consultant since April 2019. Prior to joining our company, Mr. Martins was Chief Financial Officer at Revolution Medicines, Inc., from March 2018 to October 2018 where he was responsible for all aspects of the finance function including financial accounting, capital planning, audit, tax and investor relations. Before Revolution Medicines, Mr. Martins was Vice President and Head of Corporate Strategy and Investor Relations at Ultragenyx Pharmaceutical, Inc., from September 2015 to March 2018 where he was responsible for strategic planning, capital raising, investor relations and assisting business development. Prior to Ultragenyx, Mr. Martins spent nearly 10 years as a biotechnology analyst at Jefferies, Lazard, and Barclays/Lehman Brothers after holding operating roles at Chiron Corporation from 2001 to 2006. Mr. Martins earned his B.Sc. in Life Sciences from St. Xavier’s College, a M.S. degree in Biology from Virginia Tech and an M.B.A. from the Haas School of Business at U.C. Berkeley.- Ryan Martins自2019年7月起担任我们的首席财务官，此前自2019年4月起担任我们的顾问。在加入我们公司之前，马丁斯先生于2018年3月至2018年10月在RevolutionMedicines，Inc.担任首席财务官，负责财务职能的所有方面，包括财务会计，资本规划，审计，税务和投资者关系。在Revolution Medicines之前，马丁斯先生于2015年9月至2018年3月担任Ultragenyx Pharmaceutical，Inc.的Vice President兼公司战略和投资者关系主管，负责战略规划，资金筹集，投资者关系和协助业务发展。在Ultragenyx之前，Martins先生于2001年至2006年在Chiron Corporation担任运营角色后，在Jefferies，Lazard和Barclays/Lehman Brothers担任了近10年的生物技术分析师。Martins先生获得了理学学士学位。St.Xavier&8217；s College生命科学硕士学位，Virginia Tech生物学硕士学位和U.C.Berkeley Haas商学院工商管理硕士学位。
- Ryan Martins has served as our Chief Financial Officer since July 2019 and previously served as our consultant since April 2019. Prior to joining our company, Mr. Martins was Chief Financial Officer at Revolution Medicines, Inc., from March 2018 to October 2018 where he was responsible for all aspects of the finance function including financial accounting, capital planning, audit, tax and investor relations. Before Revolution Medicines, Mr. Martins was Vice President and Head of Corporate Strategy and Investor Relations at Ultragenyx Pharmaceutical, Inc., from September 2015 to March 2018 where he was responsible for strategic planning, capital raising, investor relations and assisting business development. Prior to Ultragenyx, Mr. Martins spent nearly 10 years as a biotechnology analyst at Jefferies, Lazard, and Barclays/Lehman Brothers after holding operating roles at Chiron Corporation from 2001 to 2006. Mr. Martins earned his B.Sc. in Life Sciences from St. Xavier’s College, a M.S. degree in Biology from Virginia Tech and an M.B.A. from the Haas School of Business at U.C. Berkeley.
- Hank Mansbach
Hank Mansbach自2018年12月起担任首席医疗官。在加入我们公司之前，曼斯巴赫博士在Ultragenyx PharmaceuticalInc.工作，他于2018年6月至2018年12月担任代谢和神经疾病全球临床开发主管，2017年3月至2018年6月担任全球临床开发和Ultra计划Vice President，2015年5月至2017年3月担任医疗事务Vice President。在Ultragenyx任职期间，Mansbach博士负责领导代谢紊乱的临床开发计划，并建立和领导医疗事务团队。在Ultragenyx之前，Mansbach博士于2009年8月至2015年4月担任生物制药公司Medivation，Inc.医疗事务Vice President，在恩扎鲁胺治疗晚期前列腺癌的开发和商业化中发挥了关键作用。在其职业生涯早期，Mansbach博士曾担任Valeant Pharmaceuticals的全球药物开发高级副总裁和一家制药公司Cortex Pharmaceuticals，Inc.的首席医疗官。Mansbach博士在Glaxo Wellcome从事神经病学的临床实践和研究后开始了他的行业职业生涯。他在杜克大学获得医学博士学位，在耶鲁大学获得哲学学士学位。
Hank Mansbach has served as our Chief Medical Officer since December 2018. Prior to joining our company, Dr. Mansbach was at Ultragenyx Pharmaceutical Inc., a biotechnology company where he served Head of Global Clinical Development for Metabolic and Neurologic Diseases from June 2018 to December 2018 Vice President of Global Clinical Development and Ultra Programs from March 2017 to June 2018 and Vice President of Medical Affairs from May 2015 to March 2017. During his time at Ultragenyx, Dr. Mansbach was responsible for leading clinical development programs for metabolic disorders and building and leading the Medical Affairs team. Before Ultragenyx, Dr. Mansbach served as Vice President of Medical Affairs at Medivation, Inc., a biopharmaceutical company, from August 2009 to April 2015 where he played a key role in the development and commercialization of enzalutamide for the treatment of advanced prostate cancer. Earlier in his career, Dr. Mansbach served as Senior Vice President of Global Drug Development at Valeant Pharmaceuticals and Chief Medical Officer at Cortex Pharmaceuticals, Inc., a pharmaceutical company. Dr. Mansbach began his industry career at Glaxo Wellcome after clinical practice and research in neurology. He earned his M.D. from Duke University and a B.A. in Philosophy from Yale University.- Hank Mansbach自2018年12月起担任首席医疗官。在加入我们公司之前，曼斯巴赫博士在Ultragenyx PharmaceuticalInc.工作，他于2018年6月至2018年12月担任代谢和神经疾病全球临床开发主管，2017年3月至2018年6月担任全球临床开发和Ultra计划Vice President，2015年5月至2017年3月担任医疗事务Vice President。在Ultragenyx任职期间，Mansbach博士负责领导代谢紊乱的临床开发计划，并建立和领导医疗事务团队。在Ultragenyx之前，Mansbach博士于2009年8月至2015年4月担任生物制药公司Medivation，Inc.医疗事务Vice President，在恩扎鲁胺治疗晚期前列腺癌的开发和商业化中发挥了关键作用。在其职业生涯早期，Mansbach博士曾担任Valeant Pharmaceuticals的全球药物开发高级副总裁和一家制药公司Cortex Pharmaceuticals，Inc.的首席医疗官。Mansbach博士在Glaxo Wellcome从事神经病学的临床实践和研究后开始了他的行业职业生涯。他在杜克大学获得医学博士学位，在耶鲁大学获得哲学学士学位。
- Hank Mansbach has served as our Chief Medical Officer since December 2018. Prior to joining our company, Dr. Mansbach was at Ultragenyx Pharmaceutical Inc., a biotechnology company where he served Head of Global Clinical Development for Metabolic and Neurologic Diseases from June 2018 to December 2018 Vice President of Global Clinical Development and Ultra Programs from March 2017 to June 2018 and Vice President of Medical Affairs from May 2015 to March 2017. During his time at Ultragenyx, Dr. Mansbach was responsible for leading clinical development programs for metabolic disorders and building and leading the Medical Affairs team. Before Ultragenyx, Dr. Mansbach served as Vice President of Medical Affairs at Medivation, Inc., a biopharmaceutical company, from August 2009 to April 2015 where he played a key role in the development and commercialization of enzalutamide for the treatment of advanced prostate cancer. Earlier in his career, Dr. Mansbach served as Senior Vice President of Global Drug Development at Valeant Pharmaceuticals and Chief Medical Officer at Cortex Pharmaceuticals, Inc., a pharmaceutical company. Dr. Mansbach began his industry career at Glaxo Wellcome after clinical practice and research in neurology. He earned his M.D. from Duke University and a B.A. in Philosophy from Yale University.
- Quoc Le Nguyen
Quoc Le Nguyen自2019年3月起担任我们的首席技术运营官兼质量主管。在加入我们公司之前，阮乐天曾于2015年9月至2018年7月高级副总裁，生物技术公司AduroBiotech，Inc.的技术运营和质量全球主管，负责临床供应，包括分析和工艺开发、制造，细胞治疗，小分子和抗体平台的供应链和质量。加入Aduro之前，Le-Nguyen从2007年9月到2013年9月担任Bayer AG制造业务Vice President，负责Betaferon/Betaseron特许经营权。在加入拜耳公司之前，Le-Nguyen先生曾在诺华国际公司、Chiron公司和Biomarin PharmaceuticalInc.从事生物制剂制造工作Mr.Le-Nguyen在University of California，Davis获得生物化学学士学位。
Quoc Le Nguyen has served as our Chief Technical Operations Officer and Head of Quality since March 2019. Prior to joining our company, Mr. Le-Nguyen was Senior Vice President, Global Head of Technical Operations & Quality for Aduro BioTech, Inc., a biotechnology company, from September 2015 to July 2018 where he was responsible for clinical supply including analytical and process development, manufacturing, supply chain and quality for cell therapy, small molecule and antibody platforms. Prior to Aduro, Mr. Le-Nguyen was the Vice President of Manufacturing Operations for Bayer AG from September 2007 to September 2013 where he was responsible for the Betaferon/Betaseron franchise. Prior to Bayer, Mr. Le-Nguyen worked in biologics manufacturing for Novartis International AG, Chiron Corporation and BioMarin Pharmaceutical Inc. Mr. Le-Nguyen earned his B.S. in Biochemistry from the University of California, Davis.- Quoc Le Nguyen自2019年3月起担任我们的首席技术运营官兼质量主管。在加入我们公司之前，阮乐天曾于2015年9月至2018年7月高级副总裁，生物技术公司AduroBiotech，Inc.的技术运营和质量全球主管，负责临床供应，包括分析和工艺开发、制造，细胞治疗，小分子和抗体平台的供应链和质量。加入Aduro之前，Le-Nguyen从2007年9月到2013年9月担任Bayer AG制造业务Vice President，负责Betaferon/Betaseron特许经营权。在加入拜耳公司之前，Le-Nguyen先生曾在诺华国际公司、Chiron公司和Biomarin PharmaceuticalInc.从事生物制剂制造工作Mr.Le-Nguyen在University of California，Davis获得生物化学学士学位。
- Quoc Le Nguyen has served as our Chief Technical Operations Officer and Head of Quality since March 2019. Prior to joining our company, Mr. Le-Nguyen was Senior Vice President, Global Head of Technical Operations & Quality for Aduro BioTech, Inc., a biotechnology company, from September 2015 to July 2018 where he was responsible for clinical supply including analytical and process development, manufacturing, supply chain and quality for cell therapy, small molecule and antibody platforms. Prior to Aduro, Mr. Le-Nguyen was the Vice President of Manufacturing Operations for Bayer AG from September 2007 to September 2013 where he was responsible for the Betaferon/Betaseron franchise. Prior to Bayer, Mr. Le-Nguyen worked in biologics manufacturing for Novartis International AG, Chiron Corporation and BioMarin Pharmaceutical Inc. Mr. Le-Nguyen earned his B.S. in Biochemistry from the University of California, Davis.
- Rohan Palekar
Rohan Palekar， 2012年3月加入Avanir，担任高级副总裁兼商业总监。他拥有20多年生物制药领域的经验，曾从事过很多著名品牌包括Remicade、 Stelara和研究型疗法MDV3100。他最近的商业领导职务是担任Medivation制药公司商业总监，负责所有商业活动、化学、制造和控制、医学事务和公共关系。在Medivation之前，他在强生公司工作了16年（1991年-2008年），担任过很多高级商业和战略管理职位，最近职位是强生子公司Centocor市场营销副主管，成功启动了Remicade的两项新的适应症。这之前，他是免疫学全球副主管，消费保健品和特效药市场营销负责人。他拥有阿摩司达特茅斯学院塔克商学院的工商管理硕士学位，孟买大学会计学位和法学学位。
Rohan Palekar has served as our Chief Executive Officer and a member of our board of directors since June 2018. Prior to joining our company, Mr. Palekar served as the president and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a specialty pharmaceutical company, from December 2015 to July 2017 where he led the company following its acquisition by Otsuka Pharmaceutical Co., Ltd. in 2015. Mr. Palekar also served as Executive Vice President and Chief Operating Officer of Avanir in 2015 and as Senior Vice President and Chief Commercial Officer of Avanir from March 2012 to March 2015. Prior to Avanir, Mr. Palekar served as Chief Commercial Officer for Medivation, Inc., a biopharmaceutical company, from 2008 to 2011 where he was responsible for all commercial activities, chemistry, manufacturing and controls, medical affairs and public relations functions. Prior to Medivation, Mr. Palekar spent over 16 years at Johnson & Johnson, a diversified healthcare company, in various senior commercial and strategic management roles. Mr. Palekar earned his M.B.A. from the Tuck School of Business at Dartmouth College, his B.Com. in Accounting from the University of Mumbai and his L.L.B. in Law from the University of Mumbai.- Rohan Palekar， 2012年3月加入Avanir，担任高级副总裁兼商业总监。他拥有20多年生物制药领域的经验，曾从事过很多著名品牌包括Remicade、 Stelara和研究型疗法MDV3100。他最近的商业领导职务是担任Medivation制药公司商业总监，负责所有商业活动、化学、制造和控制、医学事务和公共关系。在Medivation之前，他在强生公司工作了16年（1991年-2008年），担任过很多高级商业和战略管理职位，最近职位是强生子公司Centocor市场营销副主管，成功启动了Remicade的两项新的适应症。这之前，他是免疫学全球副主管，消费保健品和特效药市场营销负责人。他拥有阿摩司达特茅斯学院塔克商学院的工商管理硕士学位，孟买大学会计学位和法学学位。
- Rohan Palekar has served as our Chief Executive Officer and a member of our board of directors since June 2018. Prior to joining our company, Mr. Palekar served as the president and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a specialty pharmaceutical company, from December 2015 to July 2017 where he led the company following its acquisition by Otsuka Pharmaceutical Co., Ltd. in 2015. Mr. Palekar also served as Executive Vice President and Chief Operating Officer of Avanir in 2015 and as Senior Vice President and Chief Commercial Officer of Avanir from March 2012 to March 2015. Prior to Avanir, Mr. Palekar served as Chief Commercial Officer for Medivation, Inc., a biopharmaceutical company, from 2008 to 2011 where he was responsible for all commercial activities, chemistry, manufacturing and controls, medical affairs and public relations functions. Prior to Medivation, Mr. Palekar spent over 16 years at Johnson & Johnson, a diversified healthcare company, in various senior commercial and strategic management roles. Mr. Palekar earned his M.B.A. from the Tuck School of Business at Dartmouth College, his B.Com. in Accounting from the University of Mumbai and his L.L.B. in Law from the University of Mumbai.